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ABSTRACT 
Alzheimer’s Disease (AD) has a complicated pathology with many potential 
etiologies. In patients, a diagnosis of AD is confirmed at the time of autopsy by 
the presence of two major pathological hallmarks: the amyloid beta plaque (Aβ 
plaque) and the neurofibrillary tangle (NFTs). The late-onset (LOAD) form of 
this disease has no clear genetic etiology, with the exception of an increased 
risk of carrying the APOE4 allele. Therefore, research has focused on 
identifying environmental risk factors in its etiology. Our lab has a legacy of 
studying environmental exposure to lead (Pb) during early development. We 
have shown in previous publications that exposure to Pb during early life 
results in the upregulation in a number of key genes in the amyloid and tau 
pathways directly related to the development of the characteristic hallmarks of 
AD.  
In this dissertation, Manuscript I was a review of the literature related to Pb 
exposure in both children and adults, and the role Pb has in 
neurodegenerative diseases, either by workplace exposures or by 
developmental basis of diseases. The focus of the review was also to present 
evidence from our work and others to suggest the mechanism by which these 
changes occur, via potential epigenetic pathways.   
Manuscript II was aimed to investigate the involvement of epigenetic pathways 
in the developmental model of Pb exposure, in which  (wild-type mice were 
exposed to 0.2% Pb from PND 1 and 20 Western blot and RT-PCR analysis 
were performed for a number of key epigenetic marks and regulators across 
  
the lifespan in the cortex of mice developmentally exposed to Pb. Alterations 
in a number of key mediators involved in DNA methylation were identified 
across the lifespan, as well as specific alterations in histone marks involved in 
both repression (H3K27me3) and activation (H3K9Ac, H3K4me2) pathways. 
Activating histone proteins were globally downregulated in the cortex whereas 
the repression mark was increased at the end of life.  
Manuscript III, utilized the innovative technique of ChIP-seq to identify H3K9Ac 
binding peaks in the mouse genome across the lifespan of developmentally 
Pb exposed mice. Unique peaks were present in the Pb exposed animals, with 
an emphasis on peaks in the promoter were reported. Of the genes affected, it 
was found many were associated with AD pathology by utilizing the Kegg’s 
pathway thingy, specifically it was shown that genes have acetylation islands 
in or near the promoter that were differentially acetylated in Pb exposed mice 
later in life. Therefore, by these findings show that epigenetic regulation, 
specifically by H3K9Ac, could be a potential mechanism by which AD-related 
genes become upregulated late in life.  
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PREFACE 
This dissertation was prepared following the manuscript format. It has been 
divided into three manuscripts that relate to the effects of lead exposure on 
epigenetic marks and regulators. The first manuscript is a review article on the 
consequences of lead exposure in human populations, its relevance to 
neurodegenerative disease and the possibility of epigenetic involvement in this 
process, it has been accepted and published in the journal of Neurotoxicology. 
The second manuscript examines the alterations that occur to DNA 
methylation regulators and histone marks following developmental exposure to 
mice across the lifespan, this manuscript has been accepted and published in 
Alzheimer’s and Dementia: Diagnosis and Disease Monitoring Journal. The 
final manuscript identifies the effects of lead on a specific histone mark, 
H3K9Ac at various timepoints in both control and lead exposed mice across 
the lifespan, this manuscript has been prepared following the Epigenomics 
journal guidelines.  
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ABSTRACT: Lead exposure has primarily been a concern during 
development in young children and little attention has been paid to exposure 
outcomes as these children age, or even to exposures in adulthood. 
Childhood exposures have long term consequences, and adults who have 
been exposed to lead as children show a host of cognitive deficits. Lead has 
also been shown to induce latent changes in the aging brain, and has been 
implicated in the pathogenesis of neurodegenerative diseases, particularly 
Alzheimer’s Disease, and Parkinson’s.  Recent research has shown that lead 
has the ability to alter DNA methylation, histone modifications, and miRNA 
expression in experimental models, and in humans. These findings implicate 
epigenetics in lead induced toxicity, and long term changes in individuals. 
Epigenetic modification could potentially provide us a mechanism by which the 
environment, and toxic exposures contribute to the increased susceptibility of 
adult neurodegenerative disease.   
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1.0 Introduction  
 As we age our bodies grow increasingly susceptible to environmental 
injury and insults, the brain in particular is at great risk [1]. Interestingly, there 
aren’t many toxicants that are discussed in the context of age related changes 
and abnormalities. A classic neurotoxin, that has been studied for it’s role in 
childhood and developmental toxicity is the environmental agent lead (Pb). 
Historically, the toxic effects of lead have been researched and documented 
extensively as related to children and adolescents, however, the impact of 
past exposure to lead on the aging brain was not a major concern. There have 
been devastating cases of lead encephalopathy involving both adults and 
children, which is defined as a medical emergency, and observed when 
individuals have blood lead levels (BLLs) over 70 µg/dL [2]. Infants who have 
suffered acute exposure experience sever brain damage, and impaired 
neurological outcomes at doses even lower than what is considered lead 
encephalopathy (56 µg/dL) [3].  
A dangerous property of lead is it’s ability to interact and bind to calcium 
[4]. Over 95% of lead stores have been found to be deposited into bone, and it 
is considered a primary source of exposure. Measurements of both blood and 
bone lead levels provide researchers with evidence on how recent and past 
lead exposure may have occurred. Lead has been shown to be mobilized from 
the bone during periods of the human lifespan in which bone resorption/growth 
are occurring, for example during osteoporosis and pregnancy [5], giving lead 
the ability to induce toxic effects over prolonged periods of time, without recent 
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exposure. Lead has also been shown to compete with Zinc, in a number of 
physiological interactions. It has a similar affinity for motifs and receptors that 
are typically occupied by zinc, and ultimately is able to modify transcription. 
The effects of lead exposure on transcription, and it’s dynamics with zinc have 
been extensively reviewed [6] .  
 In this review, we will discuss some of the classical outcomes as a 
result of lead exposure, but will focus on the role of lead in neurodegenerative 
and adult disease. We will introduce the role lead may have in regulating gene 
expression by way of epigenetics, and provide compelling evidence for lead as 
an epigenetic modifier.  
1.1 Adult consequences of Childhood Exposure to Lead 
 Childhood exposure to environmental lead has been heavily implicated 
in cognitive dysfunction during early years. The toxicant has been identified as 
a clear disruptor of neurodevelopment in early life, shown to impair academic 
performance in school age children, and to negatively impact intelligence 
scores [7-13]. Furthermore, children who have unfortunately been exposed to 
lead during development have shown cognitive dysfunction that continues into 
adulthood. Early studies examined children who suffered from lead 
encephalopathy in the first four years of life, were found to have decreased 
scores on a battery of neuropsychological tests [14]. Similar findings were 
reported in a group of young adults (aged 19-29), who resided nearby a lead 
smelter facility during childhood [15]. More recently, a study conducted in 
Boston MA examined young adults (mean age 29) and their cognitive function, 
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by IQ tests. Individuals were known to have low-level (<10µg/dL) 
environmental lead exposure during childhood, and had measurements of 
blood lead taken at 6, 12, 18, 24 and 57 months, and again at 10 years of age 
[16]. The study reported lower IQ test scores in individuals with higher levels of 
exposure during childhood [16].   
 Longitudinal studies have been carried out to characterize the changes 
in brain development that are associated with this early exposure, namely in 
terms of brain volume reduction in specific regions.  The Cinncinatti Lead 
Study (CSL) recruited a birth cohort from Cincinnati between 1979-1984, 
infants were excluded if they had low birth weight, or medical issues [17]. The 
CSL reported childhood BLLs were associated with regions of brain volume 
reduction in adult gray matter. Specifically this loss occurred in the prefrontal 
cortex, in regions associated with executive function control, behavioral 
modulation and fine motor control [18]. Furthermore, a subset of adults were 
recruited to high resolution volumetric magnetic imaging, and these changes 
were related to mean blood levels in the first six years of life. Significant 
inverse associates between age, gray matter volume and BLLs were 
observed, with the strongest reductions in adult gray matter associated with 
BLLs measurements at 5 and 6 years of age [19]. Further analysis of this 
cohort revealed significantly decreased levels of N-acetyl asparatate 
metabolite in gray matter as measured by proton magnetic resonance 
spectroscopy [20], these findings were replicated in a similar cohort [21]. 
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These observations implicate lead in long lasting brain abnormalities that 
impact cognitive function negatively.  
1.2 Exposures in adult populations  
 Evidence that exposure to lead is associated with cognitive decline is 
present from several longitudinal and cross-sectional epidemiological studies 
in the elderly. The onset of cognitive decline is an important intermediary for 
the development of neurodegenerative diseases, specifically Alzheimer’s 
disease.  The Baltimore Memory Study (BMS) was conducted to investigate 
determinants of cognitive decline while taking into account variables such as 
socioeconomic status, and environmental exposures [22, 23]. The cohort 
included individuals aged between 50-70 years, who lived in neighborhoods 
near Baltimore MD, and measured both blood and tibia lead levels [22, 23]. 
Results from the BMS indicated mean tibia levels were inversely correlated 
with cognitive function in all six domains tested, such as executive functioning, 
processing speed, and verbal memory and learning [22, 24]. Similar findings 
were reported by the Normative Aging Study (NAS) which began in 1963 and 
was conducted at the Veterans Affairs outpatient clinic in Boston, MA [25]. 
NAS enrolled 2,000 male veterans with the goal of investigating processes 
behind normal aging. They examined lead bone levels and results of the mini-
mental state examination within this cohort, and reported higher bone levels 
are associated with worsened cognition [26, 27]. These findings were 
expanded in subsequent years, and the cohort was examined using a battery 
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of cognitive tests, such as the Wechler Adult Intelligence Scale- Revised 
results indicated a further decline in cognitive scores across all domains [28]. 
 While most of the studies performed have focused on examining 
cognitive function in males, there are a small number that have contributed to 
our understanding of the effects of lead primarily on women. The Nurse’s 
Health Study established in 1976 began to collect health information from 
registered nurses in the United States, the study has continued to monitor 
health outcome changes every two years until the present day, and has a 
participation of >90% of individuals since its establishment [29]. Weuve et al, 
reported on a subset of the Nurse’s study, and examined blood, tibia, and 
patella levels of lead in relation to current cognitive function in community 
dwelling women. The study identified the three biomarkers of lead exposure 
were associated with worsened cognitive function in women, however only 
tibia levels were significantly higher [30]. These studies were replicated by 
others, where tibia levels were significantly associated with cognitive decline 
[31].  
1.3 Occupational exposures  
 Due to our increased knowledge and awareness of the dangers of lead 
toxicity, exposures have been relatively controlled for most community 
dwelling individuals, while those exposed to lead in the workplace remain at 
risk. Both cross-sectional and longitudinal studies have been conducted in  in 
workers exposed to lead, with studies occurring both in the United States and 
abroad. The Lead Occupational Study originally began in 1982, and examined 
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288 male workers with exposure to lead for a minimum of one year, while 
working at a lead battery plant in Pennsylvania. Cognitive functions were 
analyzed using the Pittsburg Occupational Exposures Tests (POET) [32]. 
POET results of this initial analysis found only significant associations between 
bone and BLLs and psychomotor speed [33, 34]. Members of this cohort were 
analyzed again to examine longitudinal changes in cognitive function. Khalil et 
al., reported that individuals who were reexamined had lower cognitive 
performance compared to control, as well as lower cognitive performance 
longitudinally. Unlike the initial study, the cognitive disruptions were observed 
between peak tibia lead levels, spatial ability, learning and memory and overall 
cognitive scores as determined by the POET battery test.  Furthermore, when 
these results were examined by age it was determined that older individuals 
(>55 years) had more severe cognitive declines and dysfunctions than their 
younger counterparts [35].   
These findings were also observed in the Organolead study, which 
began in 1994 to examine the effects of tetraethyllead manufacturing on 
cognitive functioning, based on earlier efforts from researchers at Johns 
Hopkins [36].  The cohorts last known lead exposure was 16 years prior, 
results indicated mean tibia lead levels were inversely correlated with 
neurobehavioral tests scores in the domains of manual dexterity, executive 
functioning, intelligence and memory [37]. Individuals were examined again 
two years later, with further associations of cognitive decline in relation to tibia 
lead levels in all areas [38]. Studies abroad have also focused on studying the 
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effects of lead exposure in the workplace. The Korea Lead Study began in 
1997 and examined both current and former inorganic lead workers in the 
republic of Korea. The study employed 803 lead workers, and cognitive tests 
were employed similar to those in the organolead study, which were a 
modified version of the world health organization neurobehavioral core test 
battery [39]. Of these tests, higher lead blood levels, and not tibia lead levels 
were associated with worse performance on eight of the tests, which were 
associated with measuring executive functioning, and manual dexterity. 
Indicating BLLs as a better predictor of worse neurobehavioral scores [39]. 
The cohort was examined again following two years, measures at this time 
point showed BLLs consistent with earlier reports, with declines in both 
cognitive test scores related to manual dexterity and executive ability. 
Furthermore, individuals had worsened cognitive scores, consistent with 
cognitive decline associated with the cumulative lead exposure [40].   
 Functional associations between the cognitive deficits and anatomical 
brain changes have been undertaken by Stewart, Schwartz and colleagues on 
former organolead workers living in the eastern United States. Study 
participants were past organolead workers with 18 years mean time from their 
last exposure, and with a mean age of 56 years at time of enrollment. Bone 
lead concentrations were measured for individuals, and MRI data collected 
[41]. Cumulative lead dose was found to be associated with increased risk, 
and increased severity in white matter lesions. Investigators also observed 
total brain volume reduction, as well as reduction in specific brain regions such 
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as the cingulate gyrus, and insula. Effects observed by lead exposure were 
equivalent to reductions seen due to 5 years of aging [41]. Indicating that lead 
has a significant role in altering the architecture of the brain involved in 
cognition, and executive function and could potentially lead individuals to be 
more susceptible to the aging process.  
2.0 Neurodegenerative Disease 
 It has been well established that as humans age, they become more 
vulnerable to a host of diseases, including cardiovascular disease, cancer and 
neurodegenerative disease [42, 43]. The nature for this is elusive to 
researchers, however there are some theories in the literature in regards to 
what may occur during the course of our lifetime, to make us more susceptible 
to these devastating diseases.  Early life exposures and disease have been 
discussed since the 1980s, with the “Barker Hypothesis” that essentially states 
that adult diseases have a connection to the fetal environment, such as 
maternal stress and or diet. This early work primarily focused on adverse fetal 
events such as low birth weight, and their connections to the development of 
adult cardiovascular disease as the individual ages [44, 45]. Similarly, the 
developmental origins of health and disease (DOHaD) also describe the 
postnatal day period as a major window of vulnerability to adult latent disease, 
and just as important as the fetal environment [46].  
 It has been theorized that due to the accumulation of environmental 
stressors over the lifetime, that individuals become vulnerable to a host of 
neurological diseases. For example, the latent early life associated regulation 
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model (LEARn) describes a hypothesis in which environmental agents play a 
role in disease pathology by perturbing gene regulation in late life [47]. These 
environmental stressors are identified as “hits” that make individuals more 
susceptible to the development of neurological diseases as they age, typically 
by inducing epigenetic changes in the genome [47]. In a recent review, 
authors have described a number of exposure models that have contributed to 
the development of neurodegenerative disease, including in utero conditions, 
exposure to metals or pesticides, and dietary and lifestyle habits [48]. A 
number of studies have identified lead as a potential contributor, or risk factor 
in the development of neurodegenerative diseases. This section will focus on 
those insults that are associated with both development and occupational 
exposure to lead, pulling from both epidemiological and experimental data to 
demonstrate the potential role of lead in neurodegenerative diseases.  
2.1 Alzheimer’s Disease  
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder 
that results in brain atrophy of cortical and hippocampal areas and is 
accompanied with the development of dementia. There are two pathological 
hallmarks of the disease, the amyloid beta (Aβ) plaque, and neurofibrillary 
tangle (NFTs), both of which are formed from the abnormal processing and 
accumulation of the amyloid precursor protein (APP) and microtubule 
associated protein tau (MAPT) respectively [49] .  
 While there is limited information regarding large-scale occupational 
and developmental exposure to lead in humans and the development of AD in 
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late life, there are some unique studies that have still managed to identify 
connections between exposure, and the disease pathology. The earliest 
example was obtained from the examination of a patient post mortem who 
survived a case of severe lead encephalopathy early in life, (2 years of age). 
The individual exhibited signs of mental deterioration, cortical, temporal and 
hippocampal atrophy. But most significantly, there was a presence of both 
neurofibrillary tangles, and senile plaques [50]. Studies of organolead workers 
16 years following the post recent exposure identified strong declines in 
cognitive function, that were more associated with individuals with the 
apolipoprotein E4 (ApoE4) allele variant. APOE4 has been implicated as a 
potential risk factor in late-onset AD (LOAD) [51].  Most recently, lead 
exposure in utero has been implicated in AD [52]. Measurements in these 
individuals in young adulthood (28-30 years of age) showed  elevated 
expression of 196 genes, specifically ADAM9, RTN9, LRPAP1 that are 
involved in the clearance and production of Aβ [52].  
 Previous studies in animals have shown developmental exposure to 
lead in early life results is an observed overexpression of AD-related proteins 
in late life. Initial observations were conducted in rodent models, with lead 
exposure during postnatal day (PND) 1-20. Analysis of gene and protein 
expression in late life identified an  upregulation of APP, and the cleavage 
enzyme Beta-secretase 1 (BACE1), consequently higher levels of both 
cleavage products Aβ40 and Aβ42, which compromise Aβ plaques were also 
significantly higher [53, 54].  Further analysis of this cohort revealed that lead 
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also altered the expression of tauogenic proteins. Total tau, phosphorylated 
tau, and enzymes involved in tau phosphorylation were increased at the end 
of life in animals developmentally exposed; this was accompanied by cognitive 
deficits [55]. Results were further verified and reported in a primate model, 
with exposure to lead acetate (1.5 mg/kg/day) occurred from PND 1-400 [56-
58]. Unlike rodents, primates are able to develop Aβ plaques and 
neurofibrillary tangles, and these animals showed increased presence of both 
pathological hallmarks in late life [56, 57]. Findings in primates implicate this 
developmental lead in the production of important pathological hallmarks of 
the disease, and strengthen the potential role for lead in the developmental 
basis of AD.  
2.2 Parkinson’s Disease 
 Parkinson’s disease (PD) is a movement disorder, which is 
characterized by bradykinesia, rigidity, tremor and postural instability. 
Neuronal cell loss occurs in the substantia nigra, with primarily dopaminergic 
cells loss [59]. The first evidence that exposure to lead may contribute to the 
development of PD, was found in 1997 [60]. This pioneering study examined a 
group of patients with idiopathic PD, and their age matched controls at Henry 
Ford Medical Center in Detroit. Individuals, who had an occupational exposure 
of over 20 years of either lead-copper or lead-iron, were found to have greater 
risk for developing PD. Other studies measured levels of lead deposited in 
trabecular and cortical bone, and revealed that higher lifetime exposure to 
lead is associated with an increased risk of PD by more than two fold in 
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individuals [61]. These findings were replicated in a larger cohort of 
individuals, and tibia bone lead levels were significantly associated with an 
increased risk for developing PD [62].  
2.3 Amyotrophic Lateral Sclerosis 
 Amyotrophic Lateral Sclerosis (ALS) or more commonly known as Lou 
Gherigs disease is a neurodegenerative disease that involves the 
degeneration of lower and upper motor neurons [63]. Initial observations in 
occupationally exposed individuals identified lead as a risk factor for the 
development of ALS [64].  Further observations in US veterans examined 
mobilization of lead from bone, and the potential association with an increased 
risk of ALS. The study concluded that elevated blood lead is associated with 
higher chances of the development of ALS regardless of both bone turnover, 
or δ-aminolevulinic acid dehydratase (ALAD) genotype. Ultimately, incidence 
of ALS was higher in those individuals with past lead exposure, and an 
increase in BLLs is associated with a 2-fold increase risk for ALS [65]. These 
findings were supported by a recent meta analysis consisting of nine case-
controlled epidemiological studies of occupational lead exposure and ALS risk 
[66]. More recently, it has been investigated if individuals with single 
nucleotide polymorphisms such as the HFE-H63D, are at a greater risk for 
ALS when coupled with lead exposure. Investigators have associated patella 
lead levels with a higher incidence of ALS, and with the co-representation of 
this polymorphism, that is associated with iron overload and increased 
oxidative stress [67].  
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3.0 The Role of Epigenetics  
 The aberrant nature of sporadic neurodegenerative diseases, and the 
little to no genetic connection to their etiology points to an environmental 
component playing a role in their pathogenesis. The environment is believed 
to either be a driving factor, or to increase an individual’s susceptibility to 
neurodegeneration with age [68].  The major mechanism by which 
environmental toxicants could be playing a role in neurodegeneration is via 
epigenetic control of gene expression. Epigenetics is the study of alterations, 
or changes in gene expression without altering the underlying DNA sequence. 
Environmental agents have been heavily studied in their ability to induce 
epigenetic changes relative to diseases such as cancer, but recently these 
observations have been made for neurological diseases.  
 DNA methylation is the most common type of epigenetic regulation 
studied. It is the process by which DNA methyltransferases (DNMTs) add a 
methyl group to the 5’ position of cytosine in CpG rich regions, by way of the 
methyl donor S-adenosyl methionine (SAM) [69, 70]. Methylation patterns are 
maintained by DNA methyltransferases such as DNMT1, DNMT3a, and 
DNMT3b, and the functional consequence of the recruitment of methyl groups 
and repressive binding proteins at the promoter region of genes is association 
with repression of gene expression [71, 72]. The nucleosome is the major 
component of chromatin consisting of DNA base pairs wrapped around an 
octamer of histone proteins, composed of two copies of Histone 2A (H2A), 
H2B, H3 and H4 with modifications to the N-terminus tail typically occurring in 
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the form of methylation, acetylation and phosphorylation [73, 74]. Typically, 
acetylation at lysines on H3 and H4 are associated with regions of chromatin 
that are open to transcription, and typically indicate gene activation. Whereas 
histone methylation marks such as H3K27me3, and H3K9me3 are involved 
with gene repression. Both histone modifications and DNA methylation have 
been shown to work in tandem to regulate gene expression by altering the 
conformation and accessibility of chromatin regions [75, 76]. Epigenetic 
regulation is also maintained by noncoding RNA’s, that bind to specific mRNA 
transcripts, and inhibit their transcription [77, 78]. The field of miRNA research 
is still new, and our understanding is primitive with comparison to DNA 
methylation, and histone modifications.  
 Epigenetic changes have been identified in a wide host of disease 
states. Primarily, this work was initially performed in oncology, with distinct 
DNA methylation patterns associated with cancer subtypes [79]. This work has 
also lead to the inclusion of DNA methylation patterns as potential biomarkers 
for a number of cancers [80, 81]. Epigenetics patterns, and epigenetic 
regulation of disease has also been observed in neurological disease states, 
including neurodegenerative diseases. In blood and brain measurements of 
PD patients, differential methylation patterns were observed in a number of 
genes relative to age-matched controls [82]. Observations in cellular models of 
ALS exhibited an upregulation of DNMTs and 5-methylcystosine (5MC). These 
findings were also observed in human ALS motor neurons, implicating DNMT 
proteins as potential drivers for neurodegeneration [83]. Hypomethylation was 
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reported at the APP promoter of an AD patient and consequently an 
upregulation of APP [84]. Further genome wide methylation studies in 
postmortem patients diagnosed with late-onset Alzheimer’s disease revealed 
948 CpG sites representing 918 genes that may be associated with this form 
of the disease. Further analysis will need to be performed to identify if the 
methylation status of candidate genes actually participate in the disease 
pathology [85].  
Proteins involved in regulating histone and DNA dynamics have also 
been altered in Alzheimer’s disease patients. A number of studies have 
identified increases in histone deacetylase proteins, such as HDAC6 and 
HDAC2 while DNMT1 levels were significantly reduced [86-88]. miRNA have 
also been found to be involved in neurodegenerative diseases. MiR107 is 
known to regulate BACE1 in human frontal cortex samples from AD patients. 
During the early pathogenesis of AD miR107 is upregulated and inversely 
related to BACE1, however as the disease progresses miR107 decreases, 
BACE1 levels are upregulated, and are involved in increased Abeta 
metabolism [89]. In PD patients, miR-34b and miR-34c were downregulated 
relative to age-matched control patients [90].  
3.1 Lead as an Epigenetic Modifier 
We have seen the emergence of a strong role for lead as a potential 
modifier of gene expression via epigenetic regulation, summarized in Figure 1. 
Some of the earliest information has come from the Zawia group, at the 
University of Rhode Island in their developmental studies of lead exposure in 
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an animal model of AD (discussed above). An early study examined both DNA 
methylation regulators and histone modifications in macaca fasicularis 
exposed to 1.5mg/kg/day of lead acetate from PND1-PND400. At 23 years of 
age exposed primates were found to have decreased levels of DNMT1, 
DNMT3a, and MeCP2 proteins involved in regulation DNA methylation, as well 
as significantly lower levels of acetylated histones [58]. In the same cohort of 
animals, DNMT1 activity was also lowered following lead exposure [56]. 
Similar findings were also observed in differentiated SHSY5Y cells. Human 
neuroblastoma cells were treated with increasing concentrations of lead 
acetate, and DNMT proteins and MeCP2 were significantly decreased [91].  
 Lifespan studies in mice have revealed genome wide dysregulation of 
DNA methylation in latent life following exposure. Methylation and gene 
expression profiles were overlaid and analyzed in animals at PND20 and 
PND700 following exposure, the results indicated a global repression profile of 
genes in late life, with a small subset of genes being overexpressed [92, 93].  
Data from the Zawia lab have shown  significant decreases of DNMT1, and 
MECP2 across the lifespan of wild type mice following developmental 
exposure to lead [94].We have also identified upregulation of H3K9Ac, and 
downregulation of H3K27me3, indicating that lead has the ability to reprogram 
the epigenome across the lifespan [94].Further studies in this same cohort 
identified a dysregulation in miRNA across the lifespan a well, with significant 
changes in miRNA involved in AD pathology [95].   
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 Studies from other groups have also identified lead as a disruptor of 
epigenetic control of gene expression. In mice, perinatal exposure to lead 
resulted in a downregulation of DNMT1 and MECP2 at PND 55 in the 
hippocampus [96]. In rats chronically exposed to lead, the expression of 7 
miRNA were altered. These miRNA have been previously shown to regulate 
genes involved in neurodegeneration, and processes involved in 
synaptogenesis and neuronal injury [97]. Acetylated histone 3 levels were also 
significantly increased with lead concentration (4mg/L, and 25mg/L), and 
associated with an increased hyperactivity in rats [98]. Lead exposure in 
human embryonic stem cells has been shown to alter DNA methylation status 
of genes involved in neural signaling [99]. Further analysis by this group has 
revealed that early exposure can disrupt 5-hydroxymethylation (5hmC) at CpG 
clusters in both human embryonic stem cells and umbilical cord blood. Studies 
of lead exposure in occupational cohorts have also identified DNA promoter 
methylation changes, individuals showed hypomethylation for LINE-1 [100], 
and hypermethylation of ALAD genes [101]. Umbilical cord blood was 
obtained from the Early Life Exposure in Mexico to Environmental Toxicants 
(ELEMENT) cohort and has potentially revealed both 5mC and 5hmC genomic 
loci that could be markers for prenatal lead exposure [102]. Lead induced 
changes in methylation have also been recently reported as transgenerational, 
with incredible data indicating that a mother’s BLLs and methylation status, 
can directly impact that of her children [103]. This is the first work to indicate 
transmittable epigenetic regulation in response to an environmental toxicant.  
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4.0 Conclusion  
 The recognition of lead as a toxicant that endangers childhood welfare 
enabled many changes across the United States, and the world. Lead levels 
began to historically drop as the health dangers began to be recognized, 
leading to the current safety level of 5µg/dL [104] . These changes resulted in 
the eradication of lead based paint, as well as the removal of lead from 
gasoline [105, 106]. Despite these efforts lead exposure remains a prominent 
threat to children as well as adults across the world. In the United States, the 
current “safe” levels of exposure to lead are 5µg/dL for children. However, 
there have been studies to identify cognitive impairments at blood levels close 
to 5ug/dl, and even below, implying that there may not be any safe level of 
exposure [107-109].  
 Lead exposure still remains as a large risk for specific populations, 
specifically children. Unlike adults, children retain 32% of lead that is ingested, 
thereby making any exposure to lead that they encounter significantly 
dangerous [110]. Individuals living in urban areas, such as New Orleans are at 
great risk for exposure due to increased levels in the environment [111-113]. 
Despite regulations leading to the closing of lead smelters, areas and 
populations that have resided nearby continuously experience higher lead 
blood levels than are considered safe, and lead remains integrated in the 
environment. In 2012 a study examining BLLs in inner-city neighborhoods in 
Indianapolis IN reported 8% of children had BLLs higher than 10µg/dL [114]. 
With the passing of the new BLLs safety recommendation by the CDC, these 
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neighborhoods reported 27% of children with BLLs higher than the 5µg/dL 
[115]. In Flint MI a recent study has reported that 4.9% of children under the 
age of five had levels higher than the recommended 5µg/dL [116, 117]. 
Residential areas in developing countries are also still highly exposed to lead, 
with individuals utilizing equipment that is either made from lead, or living in 
environments where the drinking water is heavily contaminated [118-123].  
 We have presented information and arguments to explain the 
challenges that environmental lead exposure poses to the aging brain. We 
argue that lead toxicity occurs across the lifespan, and that developmental 
exposures have long term consequences. Typically adults have been lower of 
concern when it comes to classical lead toxicity due to the development of the 
blood brain barrier. Despite this, we have compiled evidence to suggest that 
even exposures that occur during adulthood are associated with devastating 
outcome. Therefore, lead remains a real and prominent threat as an agent that 
is involved in the pathology of adult disease. Not only does it contribute to 
cognitive deficits in both children and adults, it could potentially be involved in 
the etiology of several neurological diseases. The ability of lead to work by 
epigenetic processes and pathways presents as a major challenge for how 
scientists consider it’s toxicological effects. As we continue to learn and 
uncover the role of epigenetic modifications in disease, we must be wary of 
agents that have been shown to exhibit epigenetic actions, and what the 
functional consequences could be.  
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Figure 1: Epigenetic alterations following exposure to lead 1) Exposure 
has consistently shown to decrease MeCP2, and DNMT1 and DNMT3a levels 
in the literature. A decrease in these enzymes that govern DNA methylation is 
consistent with hypomethylation of genes. 2) It has also been shown to both 
induce hypermethylation when analyzed by DNA methylation arrays, and also 
promoter specific hypo/hypermethylation by groups depending on the target 
gene being studied. Observations are consistent with upregulation of the 
repressive H3K27me3 (3), and downregulation of active H3K4me2 (4), 
whereas depending on the source and timing of exposure, lead induced 
upregulation/downregulation has been observed for H3K9Ac (5). Lead 
regulation of these mechanisms affects the transcript of the target gene. 
Whereas lead induced changes in miRNA expression (6) would either 
increase the availability of miRNA to bind to mRNA of the target gene resulting 
in a change in protein levels.  
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Abstract:  
Background: Early life lead (Pb) exposure results in a latent increase in 
Alzheimer’s disease (AD) related proteins, and cognitive deficits late in life in 
both rodents and primates. This study was conducted to investigate if these 
late life changes were accompanied by epigenetic alterations 
Methods: Western blot analysis and RT-PCR were used to measure DNA 
methylation regulators (DNMT1, DNMT3a, MeCP2, MAT2A) and histone 
proteins (H3K9Ac, H3K4me2, H3K27me3). 
Results: Cerebral levels of DNMT1 and MeCP2 were significantly reduced in 
mice exposed to Pb early in life, whereas the expression of DNMT3a was not 
altered. Levels of MAT2a were increased in the Pb-exposed mice across the 
lifespan. H3K9Ac and H3K4me2, involved in gene activation, were decreased, 
while the repressive mark H3K27me3 was elevated. 
Conclusion: Epigenetic modifiers are affected by the developmental exposure 
to Pb, and may play a role in mediating the latent increases in AD related 
proteins in the brain.  
Keywords: Aging; Alzheimer’s disease; Epigenetics; Lead (Pb); Lifespan 
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I. Introduction 
According to the 2015 Alzheimer’s Report, there are currently 5.3 
million Americans living with AD [1]. The vast majority of these individuals 
(>95%) are 65 years of age or older, with a disease subtype known as late-
onset AD (LOAD). The remaining 5% of cases make up early-onset AD 
(EOAD), and  of these (<1%) are linked to mutations in one of three genes, 
Amyloid Precursor Protein (APP), Presenilin-1 (PSEN1), and Presenilin-2 
(PSEN2) [2]. LOAD is challenging to researchers, the presentation of the 
disease is sporadic as patients exhibit non-Mendelian characteristics. To date, 
there is no clear genetic etiology for LOAD, other than a risk factor of carrying 
specific susceptibility alleles [3, 4]. The single and only proven risk factor for 
the development of this sporadic form of AD is aging. These observations 
suggest the involvement of environmental and/or epigenetic factors across the 
lifespan in the initiation and development of the disease [5]. 
Early studies have provided evidence that many chronic adult diseases 
and disorders, such as cardiovascular disease, diabetes and obesity, are 
linked to environmental exposures that occurred during development [6, 7].  
Importantly, there is also a growing body of literature to support the contention 
that exposures to environmental toxins in early life contribute to the 
development of at least some of the neurodegenerative disorders [8].   
There are few epidemiological studies examining the link between 
environmental exposures and development of LOAD. These studies have 
assessed relationships between past exposures to pesticides, metals, dietary 
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changes and other environmental influences, however the results have been 
limited.  We have taken a specific interest in the environmental agent and 
heavy metal lead (Pb). Since Pb has been implicated as a neurotoxin for 
generations, and is known to have devastating consequences for the nervous 
system, specifically in children [9]. The metal is non-degradable, ubiquitously 
found in nature, has high bioavailability, can cross the blood brain barrier and 
has a long half-life [10]. Epidemiological studies assessing both occupational 
exposure and exposures in community dwelling individuals have identified Pb 
as a clear disrupter of cognitive performance and function [11, 12] 
Our lab was among the first to provide evidence that exposure to an 
environmental Pb in early life results in latent overexpression of AD-related 
proteins and histopathology in late life  [13-16]. Reports by us have also 
demonstrated a latent increase in both amyloidogenic and tauogenic proteins, 
as well as behavioral deficits in our rodent models [13, 17]. These results have 
been replicated, and further investigated in a primate model, where we have 
also reported the presence of tangles and plaques in the cerebral cortex [14, 
16]. More recently, we have shown that the changes in the expression of 
proteins such as APP, amyloid beta (Aβ) and microtubule-associated protein 
tau (MAPT) are accompanied by epigenetic changes [14, 18]. Epigenetics 
refers to the process that results in modifications in gene activity independent 
of the primary DNA sequence [19]. DNA methylation alterations and histone 
tail modifications are the most widely studied forms of epigenetic 
modifications. 
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This study documents the expression of four enzymes important in 
regulating DNA methylation and three histone modifications (two activating, 
one repressive) across the lifespan of animals that were exposed to Pb during 
a brief period of early postnatal life.   Our results provide a valuable framework 
for understanding a number of epigenetic interactions that likely play a critical 
role in the expression of neurotoxic AD-related proteins in later life.  This work 
is the first to identify epigenetic changes across the lifespan following a 
developmental exposure that has been previously shown to have significant 
increases in AD related biomarkers.   
2. METHODS 
2.1 Animal Exposure: 
C57BL/6 mice were bred in house in the Animal Care Facility at the 
University of Rhode Island, according to previously published protocols [15, 
17]. All experiments were performed in accordance with the standard 
guidelines and protocol approved by the University of Rhode Island 
Institutional Animal Care and Use Committee (IACUC) with supervision of the 
university's veterinarian. Males were divided into two groups, and used in this 
study. The control group received regular tap water, whereas the second 
group (PbE, developmental exposure) was exposed to 0.2% Pb-acetate from 
PND 1 to PND 20 through the drinking water of the dam. Animals receiving 
Pb-acetate had no observable adverse developmental deficits.  Brains were 
dissected at the following ages: PND 20, 180, 270, 540 and 700 and stored at 
-80°C until use. These animals are from the subset of the same cohort that 
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has already been characterized for Alzheimer’s pathology and behavioral 
deficits [15, 17]. 
2.2 Total RNA isolation, synthesis of cDNA, and real time PCR 
 Total RNA was isolated from the cerebral cortex following the TRIzol 
method (Invitrogen, Carlsbad, CA). Samples were checked for integrity and 
purity by NanoDrop (Thermo Fischer Scientific, Waltham MA). First strand 
complementary DNA (cDNA) was synthesized using the iScript cDNA 
Synthesis Kit (Bio-Rad, Hercules, CA). Approximately 1 µg of RNA was diluted 
in 19 µl of water, with 4 µl 5x iScript reaction mix, and 1 µl of iScript reverse 
transcriptase. Samples were incubated at 42°C for 90 minutes, followed by 
85°C for 5 minutes using the MJ Research MiniCycler PTC-150 (Bio-Rad). 
Real-time PCR was carried out in 12.5 µl reaction volumes containing 1 µl of 
cDNA template, 4.75 µl nuclease free water and 6.25 µl SYBR® Green PCR 
Master Mix (Applied Biosystems, Foster City, CA).  Real-time PCR was 
performed using the ViiA 7 Real-Time PCR System (Applied Biosystems) 
utilizing the following conditions: 50 oC for 2 minutes followed by 95 oC for 10 
minutes then 40 cycles of 95 oC for 15 seconds and 60 oC for 1 minute. 
Expression data was reported using the 2-ΔΔCT method and GAPDH mRNA as 
the endogenous control. The primer pairs used are presented in Table 1.  
2.3 Protein Extraction  
 For DNMT1, DNMT3a, and MECP2 the nuclear fraction was collected 
according to the method described by Dignam et al, with minor modifications 
[20]. Samples were homogenized in 1 ml phosphate buffer saline (PBS) at pH 
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7.4 followed by centrifugation at 2500x g for 10 minutes. The pellets obtained 
were resuspended in 5 volumes of buffer A (10 mM HEPES, pH 7.9, 1.5 mM 
MgCl2, 0.5 mM DTT, 0.5 mM EDTA, and 0.2 mM PMSF) and centrifuged at 
600x g for 2 minutes at 4°C. The pellets were resuspended in 3 volumes of 
buffer A and centrifuged at 600x g for 2 minutes at 4°C. Following 
centrifugation, pellets were then resuspended and homogenized in 5 vol of 
buffer C (20 mM HEPES, pH 7.9, 1.5 mM MgCl2, 0.5 mM DTT, 0.5 mM EDTA, 
420 mM NaCl, 20% glycerol, 0.2 mM PMSF, 2 µg/ml aprotinin, 0.5 µg/ml 
leupeptin). Suspensions were centrifuged at 12,000x g for 10 minutes at 4°C, 
supernatants were collected, frozen and stored at -80°C until use. Cytoplasmic 
protein samples were isolated using the NE-PER nuclear and cytoplasmic 
extraction reagents according to the manufacturer’s instructions (Thermo 
Fischer Scientific).  
2.4 Histone Extraction 
 Total histones were extracted using the EpiQuick Total Histone Extraction 
Kit (Epigentek, Farmingdale, NY) following the manufactures instructions, with 
minor modifications. Cortical tissue was weighed and cut into 1-2 mm pieces 
and homogenized at 200 mg/ml with prelysis buffer. The homogenate was 
centrifuged at 10,000 rpm for 1 minute at 4oC. The supernatant was discarded, 
and the pellet was resuspended in 3x volume of lysis buffer and incubated on 
ice for 30 minutes. The sample was centrifuged at 12,000 xg for 5 minutes at 
4oC and the supernatant was transferred to a fresh vial. Balance buffer was 
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added to the supernatant (0.3 mL to 1 mL supernatant). The extract was 
placed at -80°C for long-term storage.  
2.5 Western Blot Analysis 
 Protein concentration was determined by using the Micro BCA Protein 
Assay Kit (Thermo Fischer Scientific). Protein samples were then denatured 
and separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis 
(SDS-PAGE) at 150 V for 1-2 hours, and then transferred to polyvinyl 
diflouride (PVDF) membranes (GE-Healthcare, Piscataway, NJ), blocked for 1 
hour with 5% bovine serum albumin (BSA) and then immunoblotted with the 
appropriate primary antibody. For MAT2A, 40 µg of cytoplasmic extracts were 
separated on 10 % SDS-PAGE gels and incubated overnight with primary 
polyclonal antibody at the dilution 1:1000 of ab77471 (Abcam, Cambridge, 
UK). Membranes were then stripped and reprobed with 1:2000 dilution of 
monoclonal A3854 (Sigma-Aldrich, St. Louis, MO) for β-actin. For DNMTs and 
MeCP2 proteins, 100 µg of nuclear extracts were separated on 5% SDS-
PAGE gels and incubated overnight with primary monoclonal antibodies (Cell 
Signaling, Danvers, MA) 1:1000 dilution of D59A4 for DNMT1, D23G1 for 
DNMT3a and D4F3 for MeCP2. Membranes were then stripped and reprobed 
with 1:2000 dilution of G8795 (Sigma-Aldrich, St. Louis, MO) for 
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH). For histone proteins, 
the following primary polyclonal antibodies (Epigentek) were employed at a 
1:5000 dilution, A-4022 for H3K4me2, A-4022 for H3K9Ac, A-4039 for 
H3K27me3, A-4035 for H3K9me3 and A-1112 for total H3. 10µg of histones 
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were separated onto 16% gels and incubated overnight with the respective 
primary antibody. Membranes were then washed four times with tris buffered 
saline with Tween 20 (TBST), and incubated with appropriate infrared-labeled 
secondary antibody (Li-Cor, Lincoln, NE) at 1:10000 for 1 hour at room 
temperature in the dark. Infrared band signals were detected and quantified 
using an Odyssey Infrared Imaging System (Li-Cor). MAT2A protein was 
normalized against β-actin, whereas nuclear proteins were normalized against 
levels of the housekeeping protein GAPDH. Histone proteins were normalized 
against bands for total H3.  
2.6 Statistical Analysis and Data Representation: 
 Western blot analysis was performed using the Odyssey Infrared 
Imaging System (Li-Cor, Lincoln, NE). Real-time PCR analysis was completed 
using the applied biosystems ViiA7 software. Each data set has either an n=3, 
or n=4 (designated in the figure legend), the animals were measured 
independently without pooling of brain tissue or samples. Individual data 
points are presented on each graph, as well as the mean for each group. The 
vertical bars represent 95% confidence intervals and are shown for each data 
set. The significance of difference between different treatment groups was 
determined by one-way analysis of variance (ANOVA), with the Holmes-Sidak 
post hoc test using IBM SPSS statistics 21 software. The significance of 
interaction between treatment groups and time was determined by two-way 
analysis of variance. The level of significance was set at α=0.05. The change 
in protein levels with respect to each time point were analyzed by ANOVA with 
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the Dunnetts post hoc test.   
3. RESULTS 
 We have previously measured Pb concentrations in animals exposed under 
the same protocol as the one in this manuscript and found the concentration of 
Pb in the cerebellum of PND 20 rodents (0.25 +/- 0.07 µg/g) to be 
approximately three times the level seen in control animals [21]. Blood levels 
have been shown to be 46.43 µg/dl during Pb exposure but are reduced to 
basal levels in adults [13]. The current recommended levels by the CDC is that 
of 5 µg/dL, even though the blood levels in our exposure scenario are higher 
they are still consistent with the levels seen in both children and adults 
exposed to environmental Pb [22, 23].  
3.1 Effect of Pb exposure on the expression of DNMT1 and 3a protein 
 There was no significant interaction effect between Pb  treatment and time. 
The exposed mice had a statistically significant decrease in normalized 
DNMT1 levels at all time points across lifespan relative to the control animals. 
In both the control group and Pb-exposed animals DNMT1 protein expression 
was decreased at all time points relative to PND20.  (Figure 1.A).  Unlike 
DNMT1 protein levels, DNMT3a showed no significant difference between 
control and Pb-exposed animals across the lifespan of the mice (Figure 1.B).  
3.2 Levels of MeCP2 protein across the lifespan following exposure  
 MeCP2 protein levels normalized relative to GAPDH are increased at day 
270 in both the control and Pb-exposed animals; however these results are 
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not significant. Statistically significant decreases between the Pb exposed 
group and the control group are observed at day 180, and 540 as seen in 
Figure 2.A. The remaining time points exhibited no significant difference 
between Pb exposed and controls. The control group exhibited no differences 
in proteins levels from PND 20 at any other time point.  Whereas in the Pb-
exposed animals, there was significant differences in protein expression 
observed at all timepoints except for PND 270. There was also no significant 
interaction effect between Pb treatment and time.  
3.3 Protein levels of MAT2A protein across the lifespan and following Pb 
exposure  
 The cytoplasmic protein expression profile of MAT2A across the lifespan of 
control groups did not display any significant change (Figure 2). However, 
mice exposed to Pb as infants demonstrated a statistically significant increase 
in levels of MAT2A at day 270, 540, and 700 relative to control. Similarly there 
is no interaction effect between time and treatment.  
3.4 Alterations in gene expression of DNA mediators following Pb exposure  
 Changes in gene expression of Dnmt1, Dnmt3a and Mecp2 were also 
examined by Real-Time PCR analysis. We observed no significant difference 
between mRNA levels of Dnmt1, across the lifespan between the control and 
Pb exposed animals (Figure 3.A). Dnmt3a mRNA levels for the Pb exposed 
animals were elevated compared to controls across the lifespan, and 
significantly increased at PND 20 (Figure 3.B). In figure 4.C mRNA for MeCP2 
is significantly lower at PND 20 and PND 270 for the exposed group, with no 
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change at any other time point. There was no significant interaction effect for 
any of these mRNA targets.  
3.5 Effect of Pb on activating and repressive histone marks across the lifespan  
 Histone extracts were used to profile histone modification marks across the 
lifespan via western blot. The activating marks are shown in Figure 4. H3K9Ac 
protein levels were significantly lower in the Pb exposed mice for all time 
points except PND 20, as seen in Figure 4.A. In the control animals, there was 
significant differences compared to PND 20 at both PND 270 and 540, and in 
the Pb-exposed animals significance was observed at all timepoints relative to 
day 20. H3K4me2 levels have a similar trend, the Pb exposed mice have 
lower protein levels compared to controls across the lifespan, with the only 
significant decrease occurring at PND 20 (Figure 5.B). Similarly, there were no 
significant changes at any of the time points relative to day 20 in either the 
control group, or Pb-exposed group. Representative blots for H3K9Ac and 
H3K4me2 are seen in Figure 4.C, with total Histone H3 as a loading control. 
Protein levels for H3K27me3 are shown in Figure 5. H3K27me3 is a histone 
mark indicative of gene repression. Pb exposed animals showed significantly 
higher levels of H3K27me3 across the lifespan except for day 180. In the 
control animals, all time points exhibited significant differences relative to 
PND20, whereas in the Pb-exposed animals significance was only observed at 
PND 270 and PND 540. A representative blot for H3K27me3 is shown in 
Figure 5.B.  
DISCUSSION 
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 Epigenetic regulation is a complicated phenomenon with converging 
pathways involved in the regulation of gene expression. DNA methylation is 
maintained by DNA methyltransferases such as DNMT1, DNMT3a, and 
DNMT3b, and involves the recruitment of MeCP2 as well as other proteins[24]. 
Typically recruitment of methyl groups and methyl binding proteins is indicative 
of a decrease in gene expression, and is associated with repressive 
complexes [25]. Histone tail acetylation is associated with regions of chromatin 
that are open to transcription, and typically indicate gene activation. Whereas 
specific histone methylation marks such as H3K27me3, and H3K9me3 are 
associated with regions of condensed chromatin, and gene repression.  
 This in-vivo study uncovered a significant decrease in DNMT1 levels 
relative to their age-matched controls across the lifespan of mice 
developmentally exposed  to Pb , with a significant decrease in MeCP2 levels 
at some time points as well. These findings are consistent with our previously 
published results indicating that differentiated SHSY5Y cells treated with 
increasing concentrations of Pb have a significant decrease in DNA 
modification enzymes, and MeCP2 [18].  DNMT1 is an important regulator of 
tissue specific DNA methylation patterns; exposure to metals such as  Cd 
have been shown to alter the activity and protein levels of this enzyme [26]. 
We have also previously examined the ability of Pb to alter the activity of 
DNMT1 in tissue, and have found that exposure to Pb does decrease DNMT1 
activity [14]. Studies from other groups have also examined changes in protein 
levels of DNMT1, and MECP2 as a result of postnatal and perinatal Pb 
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exposure [27]. They reported a downregulation in these DNA methylation 
modifiers in the hippocampus at PND 55 following Pb exposure. Our results 
are consistent with their findings, indicating that Pb exposure down-regulates 
these proteins in the cerebral cortex, and that this repression is never 
recovered. The data points collected in our study indicate that even at PND 
700 there is downregulation of DNMT1, and MeCP2 is maintained.  
 The results obtained from studying the gene expression of these DNA 
methylation regulators leads us to believe that Pb is most likely decreasing 
their protein expression directly, and perhaps not through transcriptional 
regulation. There was no significant change in mRNA levels for DNMT1, but 
there was a decrease in protein relative to controls across the lifespan. A 
possible mechanism for this may be due to increases in protein degradation of 
DNMT1 following exposure. Similarly, MeCP2 mRNA was only significantly 
lower at the PND 20 and PND 270 time point. The most interesting 
observation obtained from the gene expression data is for DNMT3a. DNMT3a 
gene expression for the Pb treatment was higher across the lifespan, and 
significantly increased at PND 20, whereas the protein levels were not 
significantly different in the lead exposed animals relative to control. These 
data are explained by a recent finding from our lab  showing that following 
exposure to Pb, as well as an increase in miR-29b (targeting DNMT3a) at 
PND20, suggesting that the miRNA leads to a degradation of DNMT3a mRNA 
and subsequently why we don’t observe a change in DNMT3a protein levels 
[28]. The same paper reported an is an increase of miR-106 (Targeting APP) 
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at PND 700 [28]. There is also evidence that miRNA expression is effected by 
chronic Pb exposure in an adult rat hippocampus [29].  Our observations with 
DNMT3a are also consistent with previously published work by our lab 
indicating that DNMT3a gene expression is 2 fold decreased at PND 700 for 
the Pb treated group as compared to PND 20 in primates [30].  
 MAT2A catalyzes the formation of S-adenosylmethione (SAM) from 
methione and ATP and is an important regulator of the methylation cycle. It 
has been well documented that SAM levels have been found to be 
significantly decreased in the cerebrospinal fluid of patients with AD [31]. In 
our study we have shown that Pb exposed mice have elevated levels of 
MAT2A across the lifespan compared to their age matched controls. A recent 
study in hepatoma cells has shown that upon hypoxia exposure, DNA 
demethylation pathways are activated whereas MAT2A expression is up-
regulated. [32]. In order to better understand the role of MAT2A and the 
changes of gene expression we will have to further investigate it’s role in 
regulating the DNA methylation pathway in our model.  
 Histone modifications refer to additions of chemical groups to N-terminus 
tail of histone proteins, most commonly the histone core proteins, H3 and H4. 
Histone acetylation levels are governed by histone acetyltransferases (HATs) 
and deacetylases (HDACs), whereas histone methylation by histone 
methyltransferases (HMTs). It is known that histone modifications and DNA 
methylation interact to alter the conformation, and thus the accessibility, of the 
promoter and coding regions of the genome [33]. In this study, we have shown 
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that early life Pb exposure was found to decrease H3K9Ac, and H3K4me2 
proteins levels, both of which are marks for gene activation. We have also 
shown that H3K27me3 levels are increased, which also is indicative of gene 
repression. These are consistent with our previous findings in our primate 
tissue, where we observed that histone repressive marks were upregulated, 
and the majority of genes are downregulated following Pb exposure[34].  
Although much information can be gained from understanding the 
changes in the regulation of DNA methylation enzymes and proteins, we are 
limited in that we have not identified specific genes that are directly affected in 
the alteration of binding of these modifiers. We are also trying to investigate 
the mechanisms by which Pb exposure may contribute to the dysregulation of 
these proteins. It appears from these studies and previous studies, that 
following Pb exposure there are groups of genes that are upregulated, and 
others that are repressed. This upregulation of specific genes may be 
facilitated by DNA hypomethylation, whereas the gene repression may be 
histone-mediated. The changes that have been previously reported in this 
animal model report increases in AD related proteins latent in life, whereas the 
dysregulation observed in the epigenetic regulators occurs throughout the 
lifespan [15, 35]. Future studies will examine the alterations in DNA 
methylation, as well as histone modifications that occur at specific genes and 
the consequences that has for the expression of those genes. The implications 
of this work and the findings obtained from studying histone modifications and 
DNA methylation are vast. Targeting epigenetic marks is becoming recognized 
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as a novel therapeutic approach for neurodegenerative disease, including AD 
[36]. Treatments that have been explored include histone deacetylase (HDAC) 
inhibitors, such as valproic acid, and S-adenosylmethionine supplementation 
as a method to target DNA methylation changes [36].  
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Figure 1  
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Figure 1: DNA methyltransferase  (DNMT) protein levels across the 
lifespan following developmental exposure to lead (Pb). (A) Quantification 
of DNMT1 protein expression levels across the lifespan for control animals 
and those developmentally exposed to Pb. (B) Quantification of DNMT3a 
protein levels across the lifespan following developmental Pb exposure. (C) 
Representative DNMT1 and DNMT3a proteins levels. Nuclear extracts were 
used and proteins were measured by western blot analysis as described in the 
methods section. Individual data points are represented on the graph, as well 
as the means for each time point. N=3 and significance is represented as 
*P<0.05, ** P<0.01, *** P<0.001. † is used to denote significance from the 
PND20 group for the control animals, while # is used to denote significance 
from the PND20 time point for the lead exposure group.
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Figure 2 
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Figure 2: Methyl CpG binding protein 2 (MeCP2) and Methionine 
adenosyltransferase 2a (MAT2a) levels across the lifespan following 
developmental exposure to lead (Pb). (A) Quantification of MeCP2 protein 
expression levels across the lifespan for control animals and those 
developmentally exposed to Pb. (B) Quantification of MAT2A protein 
expression levels across the lifespan for control animals and those 
developmentally exposed to Pb. (C and D) Representative MeCP2 and 
MAT2A protein levels. Nuclear and cytoplasmic extracts were used and 
proteins were measured by western blot analysis as described in the methods 
section. Individual data points are represented on the graph, as well as the 
means for each time point. N=3 for MeCP2 and N=4 for MAT2A and 
significance is represented as *P<0.05, ** P<0.01, *** P<0.001. † is used to 
denote significance from the PND20 group for the control animals, while # is 
used to denote significance from the PND20 time point for the lead exposure 
group 
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Figure 3 
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Figure 3: mRNA levels of DNA methylation regulators across the lifespan 
following developmental exposure to lead (Pb). (A) Quantification of 
DNMT1 mRNA across the lifespan for control animals and those 
developmentally exposed to Pb. (B) Quantification of DNMT3a mRNA across 
the lifespan for control animals and those following infantile exposure. (C) 
Quantification of MeCP2 mRNA across the lifespan for control animals and 
those developmentally exposed to Pb. Individual data points are represented 
on the graph, as well as the means for each time point. N=3 or N=4 and 
significance is represented as *P<0.05, ** P<0.01, *** P<0.001. † is used to 
denote significance from the PND20 group for the control animals, while # is 
used to denote significance from the PND20 time point for the lead lead 
exposure group.  
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Figure 4  
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Figure 4: Activating histone protein levels across the lifespan following 
developmental exposure to lead (Pb). (A) Quantification of H3K9Ac protein 
expression levels across the lifespan for control animals and those 
developmentally exposed to Pb. (B) Quantification of H3K4me2 protein levels 
across the lifespan following developmental Pb exposure. (C) Representative 
histone proteins levels. Histone extracts were used and proteins were 
measured by western blot analysis as described in the methods section. 
Individual data points are represented on the graph, as well as the means for 
each time point. Individual data points are represented on the graph, as well 
as the means for each time point. N=3 and significance is represented as 
*P<0.05, ** P<0.01, *** P<0.001. † is used to denote significance from the 
PND20 group for the control animals, while # is used to denote significance 
from the PND20 time point for the lead exposure group. 
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Figure 5  
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Figure 5: Repressive histone mark levels across the lifespan following 
developmental exposure to lead (Pb). (A) Quantification of H3K27me3 
protein expression levels across the lifespan for control animals and those 
developmentally exposed to Pb. (B) Representative H3K27me3 protein levels. 
Histone extracts were used and proteins were measured by western blot 
analysis as described in the methods section. Individual data points are 
represented on the graph, as well as the means for each time point. N=3 and 
significance is represented as *P<0.05, ** P<0.01, *** P<0.001. † is used to 
denote significance from the PND20 group for the control animals, while # is 
used to denote significance from the PND20 time point for the lead 
exposure group. 
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Abstract 
Introduction: Early life exposure to lead (Pb) has been shown to increase 
biomarkers involved in Alzheimer’s disease (AD) pathology in wild-type mice in 
late life. In this same cohort, we observed significant changes in both activating 
and repressing histone proteins.  
Methods: Chromatin Immunopercipitation Sequencing (ChIP-seq) technology 
was used to map histone acetylation at lysine 9 (H3K9Ac) binding to the mouse 
genome. Using bioinformatics methods we were able to align sequence reads to 
the genome, and then filter and examine the unique peaks from the Pb exposed 
group at each timepoint.  
Results: Developmental exposure to lead increases H3K9Ac at a number of 
gene promoters in animals previously exposed to Pb across the lifespan. A 
number of these genes have been implicated in AD pathology.  
Discussion: The increase of H3K9Ac peaks at the promoter of genes at day 700 
indicates that there is a high chance that they are upregulated. Specifically the 
presence of the activation mark at AD promoter supports our hypothesis for the 
role of histone proteins in our model.   
 
 
 
 
Keywords: Alzheimer’s Disease; Epigenetics; Histone Acetylation; Lead (Pb)  
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1. Introduction 
Environmental exposures have long been postulated to play a pivotal role 
in both promoting, as well as preventing disease. Numerous studies identify 
positive habits such as a healthy diet rich in polyphenols, regular exercise, caloric 
restriction and others as safeguarding against most cancers, metabolic 
syndrome, and neurological disease [1, 2]. Conversely, exposures from toxins 
and toxicants have been adversely associated with disease states. Among these 
are an increased risk of type two diabetes as a result of exposure from food 
contaminants such as persistent organic pollutants (POPs)[3]. Recent findings 
have also shown significantly increased levels of the organochloride β-
hexachlorocyclohexane (β-HCH) in patients with Parkinson’s disease relative to 
their age-matched controls [4]. Similarly serum levels of DDE the metabolite of 
DDT were 3.8 fold higher in patients with Alzheimer’s disease (AD) [5].  
The critical window for exposure in adult diseases occurs during early 
development, including both perinatal and postnatal exposures. Evidence for an 
increased risk of disease states has been referred to as the developmental basis 
of disease, and has been tied to many adverse states including metabolic 
syndrome and neurological diseases [6-8]. Specifically in AD, where the vast 
majorities of cases are late-onset with no clear etiology, the environment is 
thought to play a major role [9]. One proposed mechanism by which the 
environment may alter the expression of genes and predispose to AD is via 
epigenetic pathways [9, 10].  
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Epigenetic mechanisms refer to changes in our genome that affect gene 
expression without altering the underlying DNA sequence. Of these, the most 
commonly studied are DNA methylation and histone modifications. DNA 
methylation involves the addition of methyl groups to the cytosine residues of 
DNA. Recruitment of methyl groups to CpG islands of genes is usually involved 
in silencing of that particular region of the genome [11-13].  In the cell, DNA is 
organized around histone proteins, and histone tails can be modified by a 
number of posttranslational modifications that will either repress or enhance gene 
expression. Both DNA methylation and histone modifications work by recruiting 
other chromatin binding proteins to alter the structure of chromatin and recruit 
either activating or repressive elements [14, 15]. Specifically histone acetylation 
is involved in active gene expression, and is associated with loose binding of the 
histone proteins to the DNA, which in turn allows inclusion of transcriptional 
machinery [14, 15]. 
Our lab has extensively shown that early life exposure to lead (Pb) can 
have significant impacts on behavior in mice, and that this exposure is also 
associated with an increase in proteins involved in Alzheimer’s pathology. 
Specifically, we have reported statistically significant protein and mRNA levels of 
the amyloid precursor protein (APP) and microtuble associated protein tau 
(MAPT) in those animals exposed to Pb [16, 17] . These mice were also shown 
to have behavioral deficits at 18  and 24 months of age as measured by both the 
water maze and Y-maze [18]. Recently, this same cohort was found to have 
alterations of proteins involved in modifying epigenetic marks such as DNA 
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methyltransferases, as well as significant changes in epigenetic marks 
themselves; including significant decreases in total protein levels of H3K9Ac, an 
important histone mark involved in gene activation [19] . 
  In this study, we have used a novel approach to examine H3K9Ac binding 
across the genome. There are a limited number of papers that utilize Chromatin 
Immunoprecipitation  Sequencing (ChIP-seq) in brain tissue, as well as across 
the lifespan. There are only a handful of studies that implement similar research 
designs. A recent study reported genome wide alterations in histone acetylation 
at sites H3K9 and H3K14 by using microarray analysis in a mouse model of 
Huntington’s disease [20].  H4K12 was also examined using ChiP-seq 
technology following learning and memory experiments in mice [21]. To the best 
of our knowledge, this is the only study in which the active histone mark 
(H3K9Ac) was analyzed across the lifespan as well as following an early life 
developmental exposure.   
 In this manuscript we performed ChIP-seq analysis across the lifespan in 
animals previously exposed to Pb compared to their age matched controls. 
Tissue samples from three time points, PND 20, 270 and 700, were profiled for 
H3K9Ac binding.  
2. Methods 
2.1 Animal Exposure:  
 C57BL/6 mice were bred in house in the Animal Care Facility at the 
University of Rhode Island according to previously published protocols [19, 22, 
23]. Postnatal day 1 (PND 1) was designated as 24 h after birth. Male pups from 
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different dams were pooled and placed randomly to different dams 
(10 mice/dam). The mice were divided into two groups, the control group 
received regular tap water, and the second group (PbE, developmental 
exposure) was exposed to 0.2% Pb acetate from PND 1 to PND 20 through the 
drinking water of the dam. Cerebellar tissue from mice aged PND 20, 270, and 
700 were used in this study.  The animals used in this study have been 
previously found to have Alzheimer’s pathology as well as behavioral deficits late 
in life [16, 22, 23]. We have also shown alterations in epigenetic regulators as 
well as epigenetic marks including histone proteins following exposure to Pb [19]. 
Specifically we observed significant decreases in levels of H3K9Ac across the 
lifespan following exposure to Pb [19].  
2.2 Tissue Fractionation and Shearing Optimization 
 Chromatin Isolation was performed using the reagents from the ChIP IT 
Express Kit (Cat # 53008, 53032 Active Motif, Carlsbad CA) with modifications 
for working with tissue samples. All solutions were prepared according to the 
manufactures instructions. 100 mg of cerebellar tissue was pooled from mice 
(n=5) and was homogenized in with 4 mL of phosphate buffer saline (PBS) (1 mL 
per 25 mg of tissue), using dounce homogenizer. The cerebellum was used due 
to its dense and abundant neuronal populations that would yield sufficient 
material for these experiments. Samples were then incubated with 180 µl of 37% 
formaldehyde and placed on a shaker at room temperature for 15 min, and 
centrifuged at 3500 rpm for 8 min at 4°C. The supernatant was discarded, and 
the pellet was resuspended with 10 mL of glycine stop fix solution and incubated 
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at room temperature for 5 minutes on a shaker. The sample was then centrifuged 
at 2500 rpm for 10 min at 4°C and pellet was washed with 1 mL ice cold PBS. 
Samples were later centrifuged at 2500 rpm for 10 min at 4°C. The pellet was 
resuspended with 1 mL ice-cold lysis buffer and incubated on ice for 40 min. 
Samples were then centrifuged at 5000 rpm for 10 min at 4°C to pellet the nuclei. 
The supernatant was discarded and 350 µl of ice-cold shearing buffer was added 
to resuspend the nuclei.  
 Samples were sonicated using a Branson sonifier 150 on level 2. Each 
sample was sonicated 4 times at 20 seconds with 40 second intervals while on 
ice.  The samples were centrifuged at 1500 rpm for 10 min at 4°C and 
supernatant collected. A 50 µl aliquot of the supernatant was set aside for DNA 
cleanup and concentration measurement, and the rest aliquoted for future ChIP 
reactions. The DNA cleanup was performed by incubating the sample with 1 µl 
RNase A at 37°C for 15 minutes, then with 10 µl Proteinase K at 42°C for 1.5 hr. 
DNA was precipitated by phenol chloroform extraction 1:1 TE saturated pH 8 
(Sigma, St Louis MO). The sample was centrifuged at maximum speed for 10 
min at 4°C and the aqueous phase moved to a fresh tube. 20 µl of 3 M Sodium 
Acetate pH 5.2 and 500 µl 100% ethanol was added to the sample followed by 
overnight incubation at -80°C. The sample was then centrifuged for 15 minutes at 
4°C, the pellet washed with 500 µl 70% ice cold ethanol, and resuspended with 
30 µl double distilled ionized (DDI) water. Samples were quantified using a 
nanodrop and run on a 2% agarose gel at 100V for 45 min. The gel was 
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visualized using the Amersham Typhoon Imager Scanner FLA 9000 (GE Life 
Sciences, Piscataway NJ) with the optimal fragment size between 200-500 bp.  
2.3 Chromatin Immunopercipitation and Validation    
 ChIP Reactions were set up in 100 µl volumes as described in the ChIP IT 
Express Kit (Active Motif) with minor modifications. The antibody concentration 
for H3K9Ac (Cat #39137 Active Motif) was used at a concentration of 5 µg 
instead of the recommended 1-3 µg. Sheared chromatin was used at a 
concentration of 30 µg. The samples were incubated overnight on a rotating 
platform, at 4°C. The rest of the protocol was followed without modification.  
DNA purification was performed using the Agencourt® Ampure XP DNA 
Purification beads (Cat #A63880 Beckman Coulter, Brea CA).  Samples were 
fully resuspended with 200 µl of Ampure XP beads, and incubated for 10 min at 
room temperature. Using a magnetic stand the samples were washed with 200 µl 
of 70% ethanol. Beads were allowed to air dry on the magnet, and DNA eluted 
using nuclease free water. DNA was quantified using Nanodrop UV/VIS 
Spectrophotometer (Thermo Scientific, Wilmington DE). To ensure successful 
chromatin, pull downs were performed. RT-PCR was performed using 
commercially available positive and negative control primers. A positive primer 
for the promoter region of GAPDH was utilized (Cat # 71018 Active Motif), the 
negative control primers used were for a gene desert on chromosome 6 (Cat # 
71011, Active Motif) and gene desert on chromosome 17 (Cat # 71012, Active 
Motif). RT-PCR was performed in 20 µl reaction volumes, utilizing 10 ng of DNA, 
10ul SYBR green PCR master mix (Applied Biosystems, Foster City, CA) and 4 
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ul of the active motif primer. RT-PCR was performed using the ViiA7 Real-Time 
PCR System (Applied Biosystems) under the following conditions: 50°C for 2 min 
followed by 95°C for 10 min, then 40 cycles of 95°C for 15 sec and 60°C for 1 
min.  Normalization of the data was performed using the ChIPed DNA of each 
sample against the inputs for each sample for both the positive and negative 
control primers using the 2-ΔΔCT method. 
2.4 Library Preparation, Quality Check and Run Conditions  
 The next generation sequencing (NGS) library was prepared using the 
Ovation Ultralow System VS2 1-16 (Cat# 0344 Nugen San Carlos, CA). The 
samples were prepared at the Brown University Sequencing Facility, according to 
the manufactures protocols. Briefly, 25 ng of ChIPed DNA was end repaired, and 
adapters were added to each sample and ligated to distinguish samples from 
each other on the flow cell. Following ligation, the samples were purified and 
amplified by 10 cycles of PCR.  Samples were quantified using the Qubit dsDNA 
BR Assay Kit (Cat # Q32850 Life Technologies, Carlsbad CA).   
 Fragment analysis was performed using the High Sensitivity NGS 
Fragment Analysis Kit (Cat# DNF-474 Advanced Analytical Technologies, 
Ankeny IA) using 2 µl of library input at a concentration of 4-6 ng/µl following the 
manufactures instructions. For each library 1:1000, 1:5000, and 1:1000 dilutions 
were made using the Kapa Library Quantification Kit (Cat #KK4873 Illumina San 
Diego, CA), each dilution  was run in triplicate on ViiA7 Real-Time PCR System 
(Applied Biosystems). Reaction volume of 20 µl were run under the following 
conditions: 95°C for 5 min, then 35 cycles of 95°C for 20 sec, 60°C for 45 sec. 
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Samples were excluded from analysis if the standard deviation from the median 
was >0.1 Ct units. The total amount of library was determined for each library 
dilution using six know amplification standards with an amplification product size 
of 462 bp. The median concentration of the library was calculated using all three 
dilutions. 
 Samples were pooled and submitted for sequencing at 20 nM 
concentration to the Bauer Sequencing Facility at Harvard University.  The 
samples were processed using the Illumina Hiseq 2500 system in rapid run mode 
producing 1 X 50 bp single reads. One sample was run on two lanes of a whole 
flow cell according to standard protocol performed at the Bauer center.  
2.5 Bioinformatics Analysis 
 The raw data from ChiP-seq was analyzed in-house at the University of 
Rhode Island by the Biomedical Research Bioinformatics Core. Each tagged 
sample was end to end aligned to the mouse genome using Bowtie2 allowing for 
one mismatch between sequences [24, 25].  Files were then converted to bed 
files using SAMtools [26]. To determine H3K9Ac sites, peak calling was 
performed using SICER peak sites in the Pb group, as well as the control group. 
The Pb data set was then filtered against the control data set for each timepoint, 
leaving only peaks unique to the Pb exposed animal. The analysis was 
performed using a false discovery rate (FDR) of 0.01, and parameters specified 
from previously published protocols [27].  Peak annotation was later performed 
using the homer program with gene ontology and genome ontology [28].   
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3. Results 
3.I H3K9Ac Promoter Analysis 
 The homer peak annotation output provided H3K9Ac peaks for all 
genomic regions including promoters, exons, introns and intergenic regions. For 
the purpose of this manuscript, these data were filtered out and the results 
reported here are only for promoter regions, defined by homer as -1000 to +1000 
bp from the transcription start site (TSS).  All comparisons were made using the 
filtered peak program from SICER, which subtracted control animal peaks at 
each timepoint from the Pb exposed animal peaks.  
 In all three data sets, peaks were sorted to corresponding genes to 
identify how many genes had increased H3K9Ac peaks in the promoter region. 
We identified 405 genes at day 20, 62 genes at day 270 and 7220 genes at day 
700 with H3K9Ac binding peaks after subtracting the control group peaks from 
each data set (Figure 1).  We then identified which genes were common between 
day 20 animals and day 700, as well as day 270 and day 700. For the day 20 
samples, 293 genes had an increase in H3K9Ac peaks in their promoter, 
whereas only 112 genes were shared with the day 700. Similarly at day 270, 48 
genes were unique, whereas 14 genes were shared with the day 700 group 
(Figure 2).  
 Data files were then run by Homer and analyzed against the Kyoto 
Encyclopedia of Genes and Genomes (KEGG). The KEGG pathway database 
has a specific pathway of genes implicated in AD (ko5010)[29, 30]. At the 
promoter level, Apbb1 was the only gene to have an increase in H3K9Ac peaks 
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at the promoter in day 20 mice. There were no genes found to have increased 
acetylation at the day 270 time-point. However, at day 700, 74 genes implicated 
in Alzheimer’s were found to have increased H3K9Ac in the promoter region 
(Figure 3). A complete list of these genes can be found in Table 1.  
 For promoter regions, visualization of H3K9Ac islands are demonstrated in 
Figure 4. The degree of abundance is presented in the top trace in the UCSC 
browser[31]. The higher degree of shading indicates the higher abundance of 
reads to that specific sequence in the genome. Three genes of interest to 
Alzheimer’s pathology are presented, Apoe, App and Mapt. In all three of the 
traces, there is a high degree of H3K9Ac binding in the region immediately 
before the first exon, and within the first exon and first intron (Figure 4). The 
acetylation peaks for a subset of the 74 genes were calculated (Figure 5). These 
gens were chosen based on their association with App and Mapt.  
3.2 Genome Wide KEGG Analysis  
 This analysis utilized the entire genomic data set including all previously 
excluded elements (exons, introns, intergenic regions) to determine statistical 
significance. Using this technique, the filtered data identified a statistically 
significant increase in H3K9Ac peaks in the Alzheimer’s pathway. At day 20, 29 
genes were identified (P=0.0225) and at day 700, 96 genes were identified 
(P=.000103). A full list of these genes can be found in Table 2.  
4. Discussion  
 ChiP sequencing is a powerful tool used to identify binding sites of 
transcription factors or histone marks to DNA regions. It is also the preferred 
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method when working with larger genomes such as the human or mouse 
genome[32]. The design and sequence run of this experiment was specifically 
chosen based on the number of reads required to detect significant changes in 
histone marks in the genome. The Encyclopedia of DNA Elements (ENCODE) 
consortia has identified the appropriate number of reads for mapping histone 
marks at a threshold greater than 10 million reads per sample [33]. This 
experiment yielded between 17-19 million reads per sample for H3K9Ac, a mark 
well known for its role in activating gene expression. Due to the abundance of 
genome reads, the analysis and figures were created to examine genes with 
increased acetylation sites in the promoter regions, rather than all genomic 
regions. Furthermore, a study by Roh et al., determined that H3K9Ac islands 
present in the promoter, as well as the 5’UTR, appear to be more involved in 
regulating gene expression than those acetylation sites present in all other 
regions of the genome [34].  
 These data indicate that there is an abundance of acetylation sites in a 
number of genes in animals developmentally exposed to Pb. Specifically, when 
we subtract the H3K9Ac peaks of the control animals at each time point from the 
Pb peaks we identified 7220 genes with distinct peaks at day 700, these effects 
were much smaller in the day 20, and day 270 timepoints (Figure 1).  From our 
data, wee see there are considereably less peaks in the day 270 timepoint, which 
would suggest that consequences of developmental exposure to Pb manifest 
themselves at the end of life. Based on these data we would expect there to be 
an upregulation at the majority of the genes at day 700, due the role H3K9Ac in 
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regulating gene expression. For genes previously examined such as those 
involved in AD, this fits our previous findings [18, 23, 35]. However, these results 
will be validated in future studies examining genes in other pathways.  
 The KEGG genomic database links genes and genetic information to 
higher order functional categories, such as molecular function and disease 
pathology [29]. Specifically, the ko0510 pathway identified 162 genes that have 
been associated with AD pathology. These genes are involved in App 
processing, Tau phosphorylation, as well as mitochondrial and calcium 
dyfunction and endoplasmic reticulum stress. At day 700, 74 of these genes have 
an increase in acetylation peaks in their promoter regions (Table 1 and Figure 3). 
This increase in H3K9Ac peaks in the promoter indicates there is a high 
likelihood that these genes would in turn be upregulated following exposure to 
Pb. When we examined the entire genome using the KEGG database, we found 
statistically significant changes in a number of genes at both the day 20 
timepoint, as well as the day 700 timepoint (Table 2). Although not the promoter 
region, these H3K9Ac could also be playing a role in regulating gene expression 
and will require further analysis.  
 Other studies have implicated histone acetylation involvement in memory 
impairment, as well as in specific gene loci related to AD [10, 36]. In vitro 
treatment with thyroid hormone lead to a decrease in H3K9Ac binding in the 
promoter of APP, and subsequently a decrease in expression, these effects were 
reduced with subsequent treatment with histone deacetylase inhibitors 
(HDAC)[37]. Similarly, in animal models of AD treatments with HDAC inhibitors 
 81 
 
have been explored as potential therapeutics and have been shown to improve 
learning and memory deficits in animals [38]. While studies have reported 
hypoacetylation at genes related to memory and learning, others similar to our 
own have identified hyperacetylation of genes involved in the pathology [39]. The 
relationship between histone acetylation and AD is complex, and likely involves 
both cases of hypo as well as hyperacetylation of genes, as recently reviewed 
[36].  
 These data will be further analyzed using bioinformatics methods utilizing 
the entire genome, as well as specified promoter inputs. Although we focused 
our analysis on the promoter region in this manuscript due to the importance of 
acetylation sites in this region, there are known regulation sites throughout the 
genome further than 1000 bp from the TSS [40]. These enhancer elements have 
been shown by others to also interact with histone proteins to influence gene 
expression [40].  We will also analyze samples across time, independent of 
normalization to the control animals to identify ways in which Pb exposed mice 
differ from one another across their lifespan in acetylation peaks, the same 
analysis will be performed in the control group to analyze the effects of aging.  
 Although these findings are preliminary, they are novel in that we have 
identified a potential epigenetic mechanism by which these AD genes become 
upregulated in a model that we have worked with for over a decade. We have 
provided evidence for H3K9Ac as a potential regulator in a number of AD related 
gene promoters. This increase in H3K9Ac may contribute, or may be driving the 
increase in gene expression that we have seen in previous publications.   
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Figure 1. Acetylation Peaks in Promoter Regions. The total number of genes 
by time point (Blue); day 700 (red); day 270 and (green); day 20 Pb exposed 
animals normalized to their control counterparts with acetylated peaks in their 
promoter.  
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Figure 2. Common Genes with Acetylation Peaks in the Promoter Region. 
The total number of unique genes with acetylation peaks are shown for each time 
point in Pb exposed animals normalized to their control counterparts. The 
common number of genes shared between both time points is represented 
between them.  
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Figure 3. Acetylation Peaks in Promoters of Genes in the ko5010 Pathway. 
Of the 162 genes in the Alzheimer’s k05010 pathway, 74 of them have  genes 
with acetylated sites in their promoter in the Pb exposed animals at day 700 
relative to their control counterparts.  
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Figure 4. Acetylation Island Regions of AD related genes. The island filtered 
trace was created by filtering all of the control peaks from the Pb peaks at Day 
700. This was then visualized using the UCSC genome web browser. The 
shading represents relative abundance of reads at that particular site or location, 
with the darkest shading indicating the most abundant reads in that region. The 
following genes are represented, A) Apoe, B) App, and C) Mapt, all indicating an 
enrichment of H3K9Ac either at or near their promoter regions.   
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Figure 5. Promoter Acetylation of Genes involved in APP and Tau 
Pathology. Total number of acetylation sites were counted in the promoter 
region of genes involved in both APP and TAU pathology.   
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Table 1. Presence of acetylation islands in promoters of genes associated 
with AD . The gene database used for analysis was the ko5010. Genes with 
acetylation islands in the Pb exposed group at day 700, which were absent in the 
day 700 control group.   
I. Pb day 700 normalized to Control day 700 
Target genes: 74          
 
Tau regulation: Cdk5, Mapt, Gsk3b, Cdk5r1 
 
APP processing:  Apoe,  Psen2, Apbb1,  Lrp1, Psenen, App, Bace1 
 
Mitochondrial, endoplasmic reticulum dysfunction and Ca2+ signaling:   
Ndufa3, Ppp3cb, Ndufa8, Eif2ak3, Ndufc1, Ndufb7, Ppp3cc, Atp5g2, Sdhb, Plcb1, 
Adam10, Capn2, Apaf1, Atp5j, Itpr3, Atp5a1, Ndufa13, Ppp3ca, Ndufa4, Calm1, 
Cox5a,  Gnaq, Cox5b, Ndufab1, Ndufb4, Cox6a1, Cycs, Ndufa6, Ern1, Grin2a, 
Grin2d, Calm2, Ndufa5, Gapdh, Casp9, Aph1a, Ppp3r1, Grin2c, Bad, Atp5f1, Calm3, 
Cox4i1, Aph1c, Ndufb2, Atp5d, Ndufa7, Ndufs1, Grin1, Cacna1c, Uqcrq, Capn1, Itpr2, 
Atp5g3, Ndufv1, Casp7, Atp5b, Mapk1, Ndufb6, Atp5h, Ncstn, Cyc1, Atp2a2, Uqcrfs1 
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Table 2. Presence of acetylation islands in genes associated in AD as 
defined by the KEGG ko5010 database. (A) List of  genes with statistically 
significant (p <0.05) acetylation islands in the Pb exposed group at day 20, which 
were absent in the control day 20. (B). List of genes with statistically significant 
(p<0.001) acetylation islands in the Pb exposed group at day 700, which were 
absent in the day 700 control.  
 
 
 
 
 
A. Pb day 20 normalized to Control day 20 
Target genes: 29           P value:  0.022533815 
 
Tau regulation: Mapt, Cdk5r1 
 
APP processing:  Apbb1, Psen2, Lrp1, Ide 
 
Mitochondrial, endoplasmic reticulum dysfunction and Ca2+ signaling:  Cacna1c, 
Capn1, Atp2a3, Atp5o, Ndufs7, Ndufs8, Ndufb7, Uqcr10, Cox7a1, Uqcr11, Capn2, 
Cacna1d, Ndufb9, Nos1, Grin2d, Calm2, Cox7a2l, Cacna1s, Atp2a2, Cox8b, Ndufa4l2, 
Grin2c, Ndufa13 
 
B. Pb day 700 normalized to Control day 700 
Target genes: 96         P value: 0.000103327 
 
Tau regulation: Mapt, Cdk5, Cdk5r1, Gsk3b 
 
APP processing: Apoe, Psen2, Bace2, Psenen, Bace1, App, Lrp1, Apbb1 
 
Mitochondrial, endoplasmic reticulum dysfunction and Ca2+ signaling:   
Ndufa3, Ndufs7, Ppp3cb, Ndufa8, Eif2ak3, Ndufc1, Ndufb7, Ppp3cc, Atp5g2, Sdhb, 
Plcb1, Adam10, Cacna1d, Capn2, Cox8c, Apaf1, Atp5j, Itpr3, Atp5a1, Ndufa4l2, 
Ndufa13, Ppp3ca, Ndufa4, Calm1, Cox5a, Ryr3, Cox6a1, Cycs, Ndufa6, Ern1, Grin2a, 
Nos1, Grin2d, Calm2, Ide, Ndufa5, , Uqcrfs1, Cox7c, Atf6, Ppp3r1, Grin2c, Cox6b2, 
Bad, Atp5f1, Calm3, Cox4i1, Aph1c, Ndufb2, Atp5d, Uqcrb, Calm5, Ndufa7, Grin2b, 
Ndufs1, Grin1, Gnaq, Cox5b, Ndufab1, Plcb3, Ndufb4, Atp5o, Cacna1c, Uqcrq, 
Ndufa12, Capn1, Itpr2, Atp5g3, Ndufv1, Casp7, Atp5b, Mapk1, Ndufb6, Atp5h, Ncstn, 
Cacna1s, Ndufs4, Cyc1, Plcb4, Atp2a2, Casp8, Gapdh, Casp9, Aph1a, Mapk3 
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Appendix 1 
A Mechanistic Proposal for The Actions of Lead on the Aging Brain  
 
 In our model of developmental lead (Pb) exposure, male C57BL6J pups 
are exposed to 0.2% Pb acetate through the drinking water of the dam, and the 
control group receives regular tap water from postnatal day (PND) 1-20. Previous 
publications by us have shown that this level of Pb results in a concentration in 
the cerebellum of PND 20 rodents (0.25 +/- 0.07 µg/g [1], and blood lead level 
has been shown to be 46.43 µg/dl during Pb exposure, both measurements are 
undetectable in adults [2]. As amply cited in the manuscripts of this dissertation, 
we have published that this developmental exposure is accompanied by a 
transient increase during development and a latent increase in Alzheimer’s 
disease (AD) related biomarkers in old age [3-5]. We have also previously 
reported that exposure to Pb during early life results in global hypermethylation 
patterns as well as global downregulation of many genes [6, 7]. However, a small 
subset of genes exhibit either hypomethylation or are up-regulated by pathways 
independent of DNA methylation; AD-related genes are among them. 
 In manuscript III, we have reported a number of genes involved in AD with 
increased acetylation peaks in their promoter region. Histone acetylation at gene 
promoters is indicative of increased gene expression, and would support our 
model and previous findings. From these new data uncovered by our ChIP-seq 
study with histone acetylation, we hypothesize the following mechanisms of 
action by which Pb may be acting to modify gene expression.  
 Our ChiP-seq data indicates that a number of histone deacetylase (HDAC) 
genes lack histone acetylation peaks in their promoters, both in early and late in 
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life. Therefore we would expect the expression of these genes to be down-
regulated. This may be occurring by DNA methylation patterns that are more 
stable and persist over time, especially in neurons where we have little to no 
turnover in cells. Therefore, our Pb exposure may be enhancing DNA 
methylation at these gene promoters. HDAC proteins function primarily to 
deacetylate histones, if we are repressing these proteins we could then in turn be 
enhancing histone acetylation throughout the lifespan, which is what is observed 
in our data set.  
 We also believe that HDAC proteins may be directly targeted during the 
exposure period in early life due to the fact that HDAC proteins have a zinc 
finger-binding domain. Early work by the Zawia lab in the 1990s has shown that 
Pb can interact and disrupt zinc finger proteins, making HDAC proteins a prime 
target. This maybe one mechanism by which Pb is modifying gene expression 
early in life, it may also partially explain our global reprogramming of genes both 
by histone proteins as well as DNA methylation.  
 The changes observed in our animal model are greatly exacerbated in the 
aging brain, and we believe this is due to an increase in a number of different 
pathways such as, an increase in reactive oxygen species, increased 
inflammatory responses, and mitochondrial dysfunction. We believe that early life 
reprogramming of gene expression due to environmental exposure undermine 
our ability to combat insults that occurring during aging.  
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